Summit Therapeutics withdraws public offering citing unfavorable market conditions

Filed June 11, 2026 · Period ending June 10, 2026 · ~1 min read

Key Changes

• high

  Summit terminated its planned underwritten public offering on June 10, 2026, citing adverse market conditions. No securities will be sold and no capital will be raised through this offering.

  8-K: Offering Withdrawal verify on EDGAR →
• high

  Existing shareholders avoid dilution from this offering, but the company's capital needs that prompted the offering remain unaddressed and may require alternative financing.

  8-K: Offering Withdrawal verify on EDGAR →